The aim of this study was to clarify the effectiveness and safety of clomipramine (tricyclic antidepressant agent) in the treatment of premature ejaculation. Sixty-six patients complaining of premature ejaculation were evaluated with sexual history, physical examination, Meares-Stamey test and polysomnographic recording of nocturnal erections during a three-night period in our sleep laboratory. Forty of these patients showed normal erections without any evident organic causative factors for their premature ejaculation and underwent a randomized, double blind, placebo-controlled, partial crossover study comparing placebo and clomipramine (50 mg/day p.o.) for 8 weeks. Patients initially receiving placebo were then switched to clomipramine for another 8 weeks. Ability to maintain erections during sexual activity was investigated at the end of drug treatment and at the 3-month follow-up. Chi-square, McNemar and Student's t-test for unpaired data were used for statistical analysis. Thirty-three patients (82%) completed the whole treatment schedule and were further assessed. Positive clinical results were obtained in 19 patients (58%) at the end of drug administration. These results were significantly better than placebo (p <0.01). Positive results were maintained in 17 patients (52%) at the three-month follow-up. Drug-related adverse effects were seen in 8 (40%) and 2 (10%) patients in the clomipramine and placebo group, respectively. In patients with good erections and premature ejaculation without evident organic causes, clomipramine exerted a therapeutic effect significantly better than placebo.
|Number of pages||2|
|Journal||Acta Urologica Italica|
|Publication status||Published - 1995|
- premature ejaculation
ASJC Scopus subject areas